Watch List: Medical Marijuana Inc (MJNA), Earth Science Tech Inc (ETST), MassRoots Inc (MSRT)
Medical Marijuana Inc (OTCMKTS:MJNA) showing dropped of -2.21% and closed at $0.124, after gaining total volume of 7.95 million shares. Its earnings per share (EPS) is $0.01 and its beta value stands at -1.78 points and has total market capitalization of $335.33 million and a total of 3.03 billion outstanding shares.
Medical Marijuana Inc (MJNA) on March 21, 2017 announced that its major investment company AXIM® Biotechnologies, Inc. (AXIM Biotech) (AXIM), a world leader in cannabinoid research and development, has retained the services of Ora, Inc., a global Contract Research Organization (“CRO”), to perform the company’s upcoming product development (based on AXIM’ IP) and clinical trials for treating glaucoma and dry eye utilizing cannabinoid-based therapeutics. Ora is the world’s leading ophthalmology CRO for advancing products from pre-clinical through approval and post-market phases.
Ora will run the clinical programs under the supervision of Prof. Robert Ritch, Surgeon Director Emeritus and Chief of Glaucoma Services at New York Eye and Ear Infirmary of Mount Sinai School of Medicine in New York (NYEE). Prof. Ritch is a world-renowned expert in ophthalmology and glaucoma in particular, and has joined AXIM’s Advisory Board in December 2016.
“It is exciting to see AXIM start on pre-clinical efforts alongside esteemed ophthalmology professionals to develop a cannabinoid based eye drop medication that may assist glaucoma sufferers,” said Dr. Stuart Titus, CEO of Medical Marijuana, Inc. “This partnership between AXIM and Ora is another new exciting milestone for AXIM’s clinical development program, as it continues to move forward finding cannabinoid-based solutions for conditions for which there is no effective treatment.
“Over three million Americans have glaucoma, which is the second leading cause of blindness in the world, according to the World Health Organization,” Dr. Titus continued. “We anticipate this partnership to enhance AXIM’s glaucoma and xerophtalmia (dry eye) products development, ultimately improving the well-being of patients across the globe who suffer with these conditions. At this time, it is anticipated that initial development and early stage trials will be performed in Europe but Ora, Inc. will be pushing to receive DEA approval for U.S. trials once the clinical development leads to human trials.”
Earth Science Tech Inc (OTCMKTS:ETST) reported the plunge of -2.45% and closed at $1.99, with the total traded volume of 17,778.00 shares. During last trade its minimum price was $1.90 and it gained its highest price of $2.09 and has a total of 81.42 million outstanding shares.
On March 9, 2017 Earth Science Tech, Inc. (ETST), an innovative biotech company focused on cannabis (industrial hemp) and cannabinoid research and development, nutraceuticals, pharmaceuticals, and medical devices, is pleased to announce it has formulated a new Cannabis CBD-based pre-workout sports supplement with Forzagen. Additionally, the company’s joint venture with Karmavore Superfoods is off to a good start, and their chocolates (infused with ETST CBD) are selling well.
The company recently announced a joint venture with Nutrition Specialties and Forzagen, (Earth Science Tech, Enters Multi-Billion Dollar Sports Supplement Industry via Joint Venture with Nutrition Specialties and Forzagen) where Earth Science Tech and Forzagen will formulate new CBD-based sports products. Earth Science Tech will help develop the market in the United States while Forzagen will develop the market in Mexico and other international accounts. Earth Science Tech, together with Forzagen, have formulated a full-spectrum CBD-based pre-workout supplement called Black Demon 2.0. The supplement was formulated for serious athletes, and is incredibly potent. Forzagen and Earth Science Tech will be splitting both the costs and revenues of Black Demon 2.0, and it is currently in the label design phase. It is expected to be bottled and start selling within Q2 or Q3 of 2017.
“We have seen great success with our non-CBD products in the past, but we are expecting even greater success with Black Demon 2.0,” said Forzagen owner, Jose Bucay, “We’ve already have competitive athletes testing the supplement, and have nothing but positive feedback in regards to Black Demon 2.0. We think we’ve got a true hit in the making.”
MassRoots Inc (OTCMKTS:MSRT) decreased -0.61% closed at $0.890 and traded with total volume of 412,022.00 shares, while the average trading remained 633,355.00 shares. During last trade its minimum price was $0.88 and it gained the highest price of $0.92. Its market capitalization was $60.43 million.
MassRoots Inc (MSRT) on announce it has retired all convertible debt on its balance sheet. In addition, MassRoots has received substantial warrant exercises so far in 2017, significantly improving its capitalization table and cash position. The Company has more than 20,000 shareholders according to a non-objecting beneficial owners report and only one shareholder holding more than 5% of outstanding shares.
“Thanks to the strong support we’ve received from our shareholders over the past several months, we’ve been able to retire more than $1.5 million in convertible debt, significantly improve our capitalization table, and raise substantial cash to expand MassRoots’ market share within the rapidly-growing cannabis industry,” stated MassRoots Chairman and CEO Mr. Isaac Dietrich. “The weeks leading up to April 20th (4/20) are the cannabis industry’s holiday season, where dispensaries see significantly higher sales and MassRoots has historically seen a surge in web traffic, user-registrations, and media coverage. We look forward to releasing our revamped website and launching an aggressive user and dispensary on-boarding campaign within the next several weeks to fully capitalize on this holiday season.”